Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Minority Interest (2016 - 2019)

Spero Therapeutics filings provide 4 years of Minority Interest readings, the most recent being $355000.0 for Q3 2019.

  • On a quarterly basis, Minority Interest changed 0.0% to $355000.0 in Q3 2019 year-over-year; TTM through Sep 2019 was $355000.0, a 0.0% change, with the full-year FY2018 number at $355000.0, changed 0.0% from a year prior.
  • Minority Interest hit $355000.0 in Q3 2019 for Spero Therapeutics, roughly flat from $355000.0 in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $6.4 million in Q2 2017 to a low of -$3.8 million in Q4 2016.
  • Median Minority Interest over the past 4 years was $355000.0 (2017), compared with a mean of $526636.4.
  • Biggest five-year swings in Minority Interest: surged 109.32% in 2017 and later crashed 94.45% in 2018.
  • Spero Therapeutics' Minority Interest stood at -$3.8 million in 2016, then soared by 109.32% to $355000.0 in 2017, then changed by 0.0% to $355000.0 in 2018, then changed by 0.0% to $355000.0 in 2019.
  • The last three reported values for Minority Interest were $355000.0 (Q3 2019), $355000.0 (Q2 2019), and $355000.0 (Q1 2019) per Business Quant data.